PF-07284892 in Participants With Advanced Solid Tumors
Solid Tumor

About this trial
This is an interventional treatment trial for Solid Tumor focused on measuring colorectal cancer, non-small cell lung cancer, B-type Raf proto-oncogene (BRAF) mutation, Ras mutation, anaplastic lymphoma kinase (ALK)-positive, neurofibromatosis type 1 (NF1), ROS1
Eligibility Criteria
Inclusion Criteria:
- Age ≥18 years at the time of informed consent
- Histological or cytological diagnosis of ALK-positive advanced NSCLC, CRC with BRAF V600E mutation, or RAS- mutant, NF1-mutant or BRAF class 3 mutant solid tumor. Participants with ROS-positive NSCLC are also eligible for Part 1 and 2
- Documentation evidence of biomarker mutation status
- Part 3:
ALK-positive NSCLC with prior lorlatinib and no prior platinum-based chemotherapy (Cohort 1); with prior lorlatinib and prior platinum-based chemotherapy (Cohort 2); or with no prior lorlatinib (Cohort 3).
BRAF V600E mutant CRC participants resistant to BRAFi plus EGFRi (Cohort 4 ); refractory to BRAFi plus EGFRi (Cohort 5); or BRAFi plus EGFRi naïve (Cohort 6).
RAS- mutant, NF1-mutant or BRAF class 3 mutant solid tumors who have received prior SOC (Cohort 7).
Exclusion Criteria:
- Brain metastasis larger than 4 cm
- Active malignancy within 3 years
- Systemic anti-cancer therapy or small molecule therapeutics within 2 weeks prior to start of study treatment. Antibody based agents within 4 weeks prior to start of study treatment. Mitomycin C or nitrosoureas within 6 weeks prior to start of study treatment.
- For participants who may get lorlatinib or encorafenib on study, history of interstitial lung disease
- For participants who may get binimetinib on study, history or current evidence of retinal vein occlusion (RVO) or concurrent neuromuscular disorder associated with elevated creatine kinase (CK)
Sites / Locations
- Mayo Clinic in Arizona - PhoenixRecruiting
- Mayo ClinicRecruiting
- California Cancer Associates for Research and ExcellenceRecruiting
- California Cancer Associates for Research and ExcellenceRecruiting
- University of IowaRecruiting
- Henry Ford HospitalRecruiting
- START MidwestRecruiting
- Henry Ford Medical Center - ColumbusRecruiting
- Mayo Clinic in Rochester, MinnesotaRecruiting
- Memorial Sloan Kettering Cancer Center David H Koch Center for Cancer CareRecruiting
- Memorial Sloan Kettering Cancer Center Rockefeller Outpatient PavilionRecruiting
- Tennessee Oncology, PLLCRecruiting
- Tennessee Oncology PLLCRecruiting
- Tennessee Oncology, PLLCRecruiting
- The University of Texas MD Anderson Cancer CenterRecruiting
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Arm 5
Arm 6
Arm 7
Arm 8
Arm 9
Experimental
Experimental
Experimental
Experimental
Experimental
Experimental
Experimental
Experimental
Experimental
PF-07284892 monotherapy
PF-07284892 in combination with lorlatinib (Part 2)
Expansion Phase (Cohort 1)
Expansion Phase (Cohort 2)
Expansion Phase (Cohort 3)
Expansion Phase (Cohort 4)
Expansion Phase (Cohort 5)
PF-07284892 in combination with encorafenib and cetuximab (Part 2)
PF-07284892 in combination with binimetinib (Part 2)
Monotherapy dose escalation of PF-07284892 in participants with ALK- or ROS1-positive non-small cell lung cancer (NSCLC), B-type Raf proto-oncogene V600E mutation colorectal cancer (CRC), or RAS- mutant, NF1-mutant or BRAF class 3-mutant solid tumors
Combination dose escalation of PF-07284892 in combination with lorlatinib in participants with ALK- or ROS1-positive NSCLC
PF-07284892 + lorlatinib in participants with ALK+ NSCLC with prior lorlatinib
PF-07284892 + lorlatinib in participants with ALK+ NSCLC with no prior lorlatinib
PF-07284892 + encorafenib + cetuximab in participants with BRAF V600E mutant CRC with prior BRAF inhibitor (BRAFi) plus epidermal growth factor receptor inhibitor (EGFRi)
PF-07284892 + encorafenib + cetuximab in participants with BRAF V600E mutant CRC with no prior BRAFi plus EGFRi
PF-07284892 + binimetinib in participants with RAS- mutant, NF1-mutant or BRAF class 3 mutant solid tumors who have received prior standard of care (SOC)
Combination dose escalation of PF-07284892 in combination with encorafenib and cetuximab in participants with BRAF V600E mutant CRC
Combination dose escalation of PF-07284892 in combination with binimetinib in participants with Ras-mutant, NF-1 mutant or BRAF class 3 -mutant solid tumors